The rise of private travel vaccines in the UK can be attributed to several factors, including the increasing number of people travelling abroad and the growing awareness of vaccine importance (much attributed to the COVID-19 pandemic).
46% of UK adults have never heard of tick-borne encephalitis (TBE), even as cases have begun to appear in the UK and across Europe, according to Rare. research. Travel volumes have rebounded post-COVID, but consumer awareness of the diseases that travel vaccines protect against has not kept pace. The growth of the UK private travel vaccine market is being held back by a deeper consumer education gap, not a supply problem.
Why are travel vaccines important?
Travel vaccines protect against a wide range of diseases that range from mild infections to life-threatening illnesses. They also protect public health more broadly, since travellers who contract diseases abroad can carry them back into their home communities, especially affecting people with weakened immune systems including children, the elderly and those with underlying medical conditions.
UK healthcare professionals typically recommend vaccinations against Hepatitis A and B, Typhoid and Rabies for international travel, with destination-specific recommendations layered on top. Yellow fever, cholera, Japanese encephalitis and TBE are required or recommended depending on the country of travel. Travellers should always consult a healthcare provider or travel clinic before booking, but a significant share of the UK population does not.
How aware are UK adults of travel-related disease risk?
Awareness gaps are wide and consequential. 46% of UK adults have never heard of TBE, despite the virus now being identified in UK ticks alongside its established presence across Europe. A separate study by a leading travel insurer found that 32% of UK adults did not believe they needed to be vaccinated before travelling to another country.
That second number is the harder one to address commercially. The UK consumers who do not believe they need vaccination are not actively avoiding it, they simply do not know it should be on their pre-travel list. Public-facing campaigns from healthcare providers, travel clinics and government travel-advice channels are all needed to close the gap.
The 32% number does the work in this analysis. Roughly a third of UK adults do not believe vaccination is a relevant pre-travel step, regardless of destination. That is not vaccine hesitancy in the traditional sense. It is closer to a structural awareness gap, and it shapes the addressable market for UK private travel vaccines in a way most providers do not plan around.
Provider strategy that targets the consumer who already knows they need vaccination is competing in a small market. Provider strategy that targets the 32% who do not believe vaccination applies to them, through travel agents, airlines, school holiday channels, and pre-departure communications, is competing in a much larger one. The educational layer underneath the booking moment is where UK private travel vaccine demand expands, not where it is harvested.
